Last reviewed · How we verify

non-biological DMARDs — Competitive Intelligence Brief

non-biological DMARDs (non-biological DMARDs) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-biological DMARD (Disease-Modifying Antirheumatic Drug). Area: Immunology.

marketed Non-biological DMARD (Disease-Modifying Antirheumatic Drug) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

non-biological DMARDs (non-biological DMARDs) — Hoffmann-La Roche. Non-biological DMARDs are small-molecule drugs that suppress the immune system by inhibiting intracellular signaling pathways to reduce inflammation and joint damage in autoimmune diseases.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
non-biological DMARDs TARGET non-biological DMARDs Hoffmann-La Roche marketed Non-biological DMARD (Disease-Modifying Antirheumatic Drug)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-biological DMARD (Disease-Modifying Antirheumatic Drug) class)

  1. Hoffmann-La Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). non-biological DMARDs — Competitive Intelligence Brief. https://druglandscape.com/ci/non-biological-dmards. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: